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Up to 40 percent of new chemical entities discovered by the pharmaceutical indus-
try today are poorly soluble or lipophilic compounds. The solubility issues complicating
the delivery of these new drugs also affect the delivery of many existing drugs (1). Po-
orly water-soluble drugs show unpredictable absorption, since their bioavailability de-
pends upon dissolution in the gastrointestinal tract (2–4). The dissolution characteristics
of poorly soluble drugs can be enhanced by several methods (5–7). Solid dispersion is
one of the effective and widely used techniques for dissolution enhancement (8). The
two basic procedures used to prepare solid dispersions are the melting or fusion (9) and
solvent evaporation (10) techniques. The increase in dissolution rate for solid dispersions
can be attributed to a number of factors (11), which include reduction in particle size,
absence of aggregation or agglomeration of fine crystallites of the drug, possible solu-
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The objective of the present investigation was to study
the effect of polyethylene glycol 4000 (PEG 4000) on in
vitro dissolution of gliclazide from solid dispersions. Ini-
tial studies were carried out using physical mixtures of
the drug and carrier. Solid dispersions were prepared by
the melting or fusion method.
Phase and saturation solubility study, in vitro dissolution
of pure drug, physical mixtures and solid dispersions were
carried out. PEG was found to be effective in increasing
the dissolution of gliclazide in solid dispersions when
compared to pure drug. FT-IR spectroscopy, differential
scanning calorimetry and X-ray diffractometry studies
were carried out in order to characterize the drug in the
physical mixtures and solid dispersions. Dissolution en-
hancement was attributed to decreased crystallinity of the
drug and to the wetting and solubilizing effect of the
carrier from the solid dispersions of gliclazide. In con-
clusion, dissolution of gliclazide can be enhanced by the
use of hydrophilic carrier.
Keywords: gliclazide, solid dispersions, polyethylene
glycol
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bilization effect of the polymer, excellent wettability and dispersibility of the drug from
solid dispersion and partial conversion of the drug into amorphous form.
Gliclazide 1-(3-azabicyclo (3,3,0)oct-3yl)-3-p-tolyl-sulphonylurea is a second gene-
ration, hypoglycemic sulphonylurea (12) and is used in the treatment of non-insulin de-
pendent diabetes mellitus. Due to short duration of its action, it is considered suitable for
diabetic patients with renal impairment and for elderly patients that have reduced renal
function and follow a sulphonylurea treatment, which may increase the risk of hypo-
glycemia (13). Because of its low solubility and low dissolution in gastric fluids, it shows
variation in bioavailability (14).
Polyethylene glycol (PEG) is used for the preparation of solid dispersions. A parti-
cular advantage of PEGs for the formation of solid dispersions is that they have good
solubility in many organic solvents. The melting point of PEGs lies below 65 °C in all
cases (15), which is advantageous for the manufacture of solid dispersions. Additional
attractive features of PEGs include their ability to solubilize some compounds (16) and
also improve compound wettability. Therefore, in the present study, it was chosen as a
suitable polymer for the preparation of solid dispersions. Solid dispersions were then
evaluated by dissolution, FT-IR spectroscopy, differential scanning calorimetry (DSC)
and X-ray diffractometry (XRD).
EXPERIMENTAL
Materials
A gift sample of gliclazide was received from Indi Pharma Pvt. Ltd. (India) and PEG
4000 was purchased from Qualigens Fine Chemicals (India).
Methods
Physical mixtures of gliclazide. – Physical mixtures of gliclazide at three different mass
ratios (1:1, 1:3 and 1:5) were prepared in a glass mortar by light trituration for 5 minutes.
The mixtures were passed through a sieve. The prepared mixtures were then filled in
glass bottles, sealed and stored in a dessicator until further use.
Solid dispersions of gliclazide. – Solid dispersions of gliclazide at three mass ratios
(1:1, 1:3 and 1:5) were prepared by the melt or fusion method. PEG 4000 was placed in a
porcelain dish and allowed to melt by heating up to 70 °C. To the molten mass, an ap-
propriate amount of gliclazide was added and stirred constantly until homogenous dis-
persion was obtained. For rapid solidification, the resultant solution was cooled in an ice
bath and stored in dessicator for 24 h. It was then scrapped, pulverized and passed
through a sieve. The prepared solid dispersions were then filled in glass bottles, sealed
and stored in a dessicator until further use.
Drug content. – The drug content in each solid dispersion and physical mixture was
determined by the UV-spectroscopic method. An accurately weighed quantity of solid
dispersion or physical mixture, equivalent to 60 mg of gliclazide, was transferred to a
100-mL volumetric flask containing 10 mL of methanol and dissolved. The volume was
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made up to 100 mL with NaOH (0.1 mol L–1). The solution was filtered through 0.45-mm
membrane filter paper. One mL of this solution was diluted 100 times with NaOH (0.1
mol L–1) to achieve 6 mmol L–1 and the absorbance was measured at 226 nm.
Phase and saturation solubility study. – Phase and saturation solubility studies were
performed according to the method described by Higuchi and Connors (17). Pure glicla-
zide (50 mg) and a quantity of physical mixture equivalent to 50 mg of gliclazide were
stirred vigorously in a water bath shaker at 37 ± 0.5 C in sealed vials with 0.1 mol L–1
hydrochloric acid (25 mL, pH 1.2) for 24 h. The sample was then centrifuged and filtered
through 0.45-mm membrane filter. After suitable dilution, the absorbance was measured
at 226 nm. For the saturation solubility study, the same treatment was applied to solid
dispersions and the concentration of gliclazide was determined.
Dissolution study. – Dissolution of gliclazide powder as such, from its physical mix-
tures and solid dispersions, was carried out with the USP dissolution test apparatus (18)
at 37 ± 0.5 °C and the 100 rpm using 900 mL hydrochloric acid buffer (pH 1.2) and phos-
phate buffer (pH 7.4) as dissolution media. Samples of dissolution medium (5 mL) were
withdrawn at predetermined time intervals and an equal volume of fresh dissolution
medium was added. Test samples were filtered through Whatman filter paper No. 41,
suitably diluted and assayed for gliclazide at 226 nm. The cumulative percentage of gli-
clazide dissolved was calculated from the regression equation generated from standard
data.
FT-IR study. – FT-IR spectra were recorded using an FT-IR spectrophotometer (Shi-
madzu). The samples (gliclazide, polymers, physical mixtures and solid dispersions) were
previously ground and mixed thoroughly with potassium bromide. Forty scans were ob-
tained at a resolution of 4 cm–1 from 4500 to 400 cm–1.
Differential scanning calorimetry study. – The DSC measurements were performed on
a DSC-60 (Shimadzu), differential scanning calorimeter with a thermal analyzer. Accu-
rately weighed samples (about 5–10 mg) were heated in hermetically sealed aluminum
pans under a nitrogen atmosphere at the flow rate of 20 mL min–1 with a scanning rate
of 15 °C min–1 from 60 to 250 °C. An empty aluminum pan was used as a reference.
X-ray diffraction study. – The crystalline state of different samples was evaluated
with X-ray powder diffraction. Diffraction patterns were obtained using an XPERT-PRO
diffractometer (PANalytical) with a radius of 240 mm. The Cu Ka radiation (Ka 1.54060
Å) was Ni filtered. A system of diverging and receiving slits of 1° and 0.1 mm, respec-
tively, was used. The pattern was collected with 40 kV of tube voltage and 30 mA of tube
current and scanned over the 2q range of 5–60°.
RESULTS AND DISCUSSION
Results depicted in Table I show that the drug concentration in physical mixtures
and solid dispersions ranged between 98.2 and 99.4 and 98.7 and 101.3 %, respectively.
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The mechanisms responsible for improved drug dissolution may be either drug/
carrier interactions in solid state or drug/carrier interactions in liquid state or both.
When the physical mixture is added to the dissolution medium, it may simply happen
that the carrier, which dissolves first, modifies the hydrophilicity/lipophilicity or wetta-
bility of the drug or it may form a weak complex with the drug at the particle surface,
resulting in drug dissolution. The results of the phase solubility study of physical mix-
tures simulating different drug: carrier mass ratios indicated that the phase solubility of
drug was enhanced to 84 % as compared to the pure drug, gliclazide. Results are pre-
sented in Figure 1.
An increase in the saturation solubility of the drug can explain the improved disso-
lution of solid dispersions as per the Noyes and Whitney equation (19), since the satura-
tion solubility of a compound is dependent on the size of the particles. Since it is possi-
ble to achieve reduction in particle size with a solid dispersion system, the saturation
solubility studies were performed with these systems. The results on saturation solubi-
lity indicated that the solubility was enhanced by 37 to 128 % compared to gliclazide.
The cumulative release of gliclazide at various time intervals from the physical mix-
tures and solid dispersions made by using various concentrations of PEG 4000 are shown
in Figs. 2a,b. Dissolution of the pure drug, gliclazide, in 0.1 mol L–1 HCl (pH = 1.2) was
only 41.2 %. Prepared physical mixtures and solid dispersions showed improvement in
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Fig. 1. Phase and saturation solubility
(X ± SD, n = 3).
Table I. Drug content in physical mixtures and solid dispersions
Physical mixture (drug
to PEG mass ratio)
Drug content (%)a
Solid dispersion (drug
to PEG mass ratio)
Drug content (%)a
PM 411 (1:1) 98.2 ± 1.9 SD 411 (1:1) 98.7 ± 0.7
PM 413 (1:3) 98.9 ± 0.5 SD 413 (1:3) 99.8 ± 2.5
PM 415 (1:5) 98.4 ± 0.5 SD 415 (1:5) 101.3 ± 1.8
a Mean ± SD, n = 3.
dissolution characteristics. In the first 30 minutes, physical mixtures of PEG 4000 (1:1,
1:3 and 1:5) showed 55.7, 53.3 and 60.2 % drug release, and 67.2, 66.0 and 53.3 % drug re-
lease from solid dispersions (1:1, 1:3 and 1:5). After 120 min, physical mixtures showed
87.3, 88.1 and 90 % drug release, whereas solid dispersions showed 90.3, 95.9 and 96.9%
drug release, respectively.
Dissolution of the pure drug, physical mixtures as well as solid dispersions was
tested in phosphate buffer (pH = 7.4) for a period of 120 minutes. Dissolution of the pure
drug was found to be 60.7 % in 120 minutes. Almost half of the drug was dissolved from
physical mixtures and solid dispersions in the first 30 minutes. In the first 30 minutes,
cumulative drug release from physical mixtures (1:1, 1:3 and 1:5) was 53.7, 56.5 and 60.7 %,
respectively, while solid dispersions showed 60.7, 63.4 and 70.7 % release. After 120 min,
solid dispersions (1:1 and 1:3) showed 96.0 and 96.6 % release whereas maximum release
was obtained with 1:5 and was 99.6%. Results are presented in Figs. 2c,d.
Possible mechanisms of increased dissolution rates of solid dispersions have been
proposed by Ford (19), and include a reduction of crystallite size, solubilization effect of
the carrier, absence of aggregation of drug crystallites, improved wettability and disper-
sibility of the drug from the dispersion, dissolution of the drug in the hydrophilic car-
rier, drug conversion to amorphous state and finally, a combination of the mentioned
mechanisms. The increased dissolution rate in these cases can thus be attributed to seve-
ral factors, such as the solubilization effect of the carrier, conversion to amorphous state,
and improved wettability of gliclazide. In general, dissolution may be described by two
processes: the rate of the interfacial or solid solvent reaction leading to solubilization of
the molecule, and the rate associated with the diffusional or transport process of the
solvated molecule to the bulk part of the dissolution medium (20). Water readily forms
hydrogen bonds with the polar groups such as OH present in PEG 4000 and the –CH3
and SO2 groups in gliclazide. The strength of bonds between water and PEG 4000 and
water and drug molecules may be stronger than or comparable with that between the
molecules of the solid dispersions. Upon contact, water molecules solvate the polymers
and gliclazide molecules, either in the crystalline or in amorphous form, and break the
hydrogen bonds in the drug-carrier complexes.
The FT-IR spectra of gliclazide, PEG 4000, physical mixture (1:5) and solid disper-
sion (1:5) are presented in Figs. 3a-d. The spectrum of gliclazide showed a sharp concave
curve at 1709 cm–1 for the carbonyl group. A symmetric stretching peak at 1164 cm–1 and
an asymmetric stretching peak at 1350 cm–1 were detected for the sulphonyl group. A
peak at 3272 cm–1 evidenced the amino group. The PEG 4000 spectrum showed impor-
tant peaks at 3425 cm–1 (OH stretch), at 1109 cm–1 (C-O-C stretch) and at 2889 cm–1 (CH
stretch). In this case, any sign of interaction would be reflected by a change in C=O, S=O
and NH vibrations in the spectrum of physical mixtures and solid dispersions, de-
pending upon the extent of interaction. From the chemical structures, hydrogen bonding
could be expected between the hydroxyl group of PEG 4000 and carbonyl function of
gliclazide and hydrogen bonding between hydrogen atom of the NH of gliclazide and
one of the ion pairs of the oxygen atom in PEG 4000. The spectra of solid dispersion and
physical mixture did not indicate any well-defined interaction between gliclazide and
PEG 4000.
The DSC thermograms of gliclazide, PEG 4000, PM 415 (1:5) and SD 415 (1:5) are
presented in Figs. 4a-d. Gliclazide showed an endothermic reaction and its melting peak
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Fig. 2. Release profile of gliclazide and a) physical mixtures in acid buffer; b) solid dispersions in
acid buffer; c) physical mixtures in phosphate buffer; d) solid dispersions in phosphate buffer.
was at 172.3 °C. The thermal behavior of PEG 4000 exhibited a sharp but slightly broad
endothermic peak at 59.2 °C. Physical mixture (PM) and solid dispersion (SD) showed a
single sharp melting peak at 60.3 and 59.3 °C, respectively. Complete disappearance of
the gliclazide melting peak observed in both PM and SD was attributable to complete
miscibility of the drug in the melted carrier. The enthalpy of drug melting in solid dis-
persion (DHu –148.3 J g–1) was gradually decreased as compared to the drug (DHu –126.9
J g–1). This phenomenon could be attributed to the amorphous form of the drug in solid
dispersion.
The diffraction spectra of pure gliclazide, PEG 4000, its physical mixture (1:5) and
solid dispersion (1:5) are shown in Figs. 5a-d. The diffraction pattern of pure gliclazide
showed that the drug was of crystalline nature, as demonstrated by numerous distinct
peaks. Gliclazide’s numerous diffraction peaks were observed at 2q of 10.5, 15.0, 16.7,
17.0, 17.8, 18.1, 18.4, 20.8, 21.1, 22.0, and 26.2, etc. (fingerprint region), indicating the cry-
stalline nature of gliclazide. Pure PEG 4000 showed two peaks with highest intensity at
2q of 19.3 and 26.2. The physical mixture and solid dispersion showed two peaks of hig-
hest intensity, at 2q of 19.1 and 23.5 attributable to PEG 4000. Solid dispersion showed
all peaks of the drug; however, the intensity of the peaks was reduced when compared
to that of the drug and hence absent. The results indicate that the drug in solid disper-
sion was amorphous as compared to the pure drug; hence the dissolution of the drug
was improved. PEG 4000 peaks in solid dispersion were the same and just superimpo-
sed, which ruled out the possibility of chemical interaction between gliclazide and PEG
4000.
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Fig. 3. FT-IR spectra of a) gliclazide; b) PEG 4000; c) physical mixture (1:5); d) solid dispersion (1:5).
CONCLUSIONS
The present work shows that the dissolution rate of gliclazide from solid disper-
sions with PEG 4000 improved to more than 90% compared to the pure drug. Further, all
the solid dispersions performed better than the corresponding physical mixtures. Also,
the saturation solubility of the drug when formulated into solid dispersion with the po-
lymer was higher than that of phase solubility achieved in the presence of the polymer.
IR spectra indicated no well-defined interaction between the drug and polymer. DSC
thermograms of physical mixture and solid dispersion indicated complete miscibility of
the drug in melted carrier. Amorphous nature of the drug in solid dispersion was con-
firmed by a decrease in enthalpy of drug melting in solid dispersion compared to the
pure drug. XRD analysis indicated a reduction in drug crystallinity in solid dispersion.
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S A @ E T A K
Priprava i karakterizacija gliklazid-polietilen glikol 4000 ~vrstih disperzija
MORESHWAR P. PATIL i NARESH J. GAIKWAD
U radu je opisan u~inak polietilen glikola 4000 (PEG 4000) na in vitro osloba|anje
gliklazida iz ~vrstih disperzija koje su pripravljene metodom taljenja ili fuzije. ^vrstim
disperzijama i fizi~koj smjesi ljekovite tvari i nosa~a prou~avana je topljivost faza i zasi-
}enje te in vitro osloba|anje ljekovite tvari. Rezultati ukazuju da PEG pove}ava osloba-
|anje gliklazida u ~vrstim disperzijama. Za karakterizaciju fizi~kih smjesa i ~vrstih dis-
perzija upotrebljena je FT-IR spektroskopija, diferencijalna pretra`na kalorimetrija i
difraktometrija rendgenskog zra~enja. Zaklju~eno je da je pove}anje osloba|anja poslje-
dica vla`enja, smanjene kristalini~nosti i solubiliziraju}eg u~inka nosa~a te da se oslo-
ba|anje gliklazida mo`e pove}ati pomo}u hidrofilnog nosa~a.
Klju~ne rije~i: gliklazid, ~vrste disperzije, polietilen glikol
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